TGFB1 and neoplasm: Recent studies have revealed that anti-TGF-β/PD-L1 bispecific antibody YM101 can simultaneously block the PD-1/PD-L1 and TGFR2/TGF-β signaling pathways, promote the activation of efficient T cells, regulate the tumor microenvironment, and reverse immunosuppression and fibrosis (132).